Biolexis division of Stelis partners with Akston for Covid-19 vaccine - AmbiVax-Ctrade

24 Mar 2022 , 01:33 AM

Akston Biosciences Corporation a developer of new classes of biologic therapeutics and Biolexis a division of Stelis Biopharma Stelis announced today that they have entered into a licensing manufacturing and commercialization agreement for Akstons AKS-452 a protein subunit COVID-19 vaccine Under the agreement Biolexis gains the right to manufacture and commercialize AKS-452 branded as AmbiVax-Ctrade; in India and over 130 countries in Asia Latin America and Africa largely covering the low-and-middle income countries LMICs Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships AKS-452 or AmbiVax-Ctrade; is a first-of-its-kind thermostable COVID-19 vaccine developed for all parts of the world AmbiVax-Ctrade; is a SARS-CoV-2 protein subunit vaccine designed to induce a Th1Th2 mixed immune response in patients against the Receptor Binding Domain RBD of the novel coronavirus spike protein As the primary locus for infection the RBD is highly conserved among mutated forms of the virus The studies on AmbiVax-Ctrade have demonstrated robust antibody neutralization of variants including Delta and Omicron and the vaccine has been evaluated in multiple safety and efficacy studies in Netherlands and India across hundreds of subjects